During the past decade, Universitätsklinikum Heidelberg - Klinik für Urologie conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Universitätsklinikum Heidelberg - Klinik für Urologie" are "Renal Cell Carcinoma" (2 trials). Many other conditions were trialed in "Universitätsklinikum Heidelberg - Klinik für Urologie" in a lesser frequency.

Most popular intervention types in "Universitätsklinikum Heidelberg - Klinik für Urologie" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Endoxana, IMA901, Leukine" (1 trials), "IMA901 and Leukine" (1 trials), "Pazopanib+Sorafenib" (1 trials) and "Sorafenib+Pazopanib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinikum Heidelberg - Klinik für Urologie" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Universitätsklinikum Heidelberg - Klinik für Urologie". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Universitätsklinikum Heidelberg - Klinik für Urologie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinikum Heidelberg - Klinik für Urologie, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".